I think its just about a done deal with the major pharma co, just look at the language between the 2 announcements, deal coming soon for sure IMHO.
14th Feb 2014
We have recently been presented with a partnership opportunity for our Virtual Tumour Clinical development. Discussions are still at an early stage, and may or may not lead to an agreement; however this collaboration would provide essential clinical calibration data as well as a route to customer validation of the model.
Today. We are also currently in discussions with the first large pharma company who will take on and help us further develop Virtual Tumour Clinical."
Surely, as far as thw wider market is concerned, "in discussions with large pharmaceutical companies" is the bit that'll grab attention? For any small development outfit like PYC, interaction with the big boys is both a proof of credibility and an indicator of the potential route to future commercial success.
It's not beyond the bounds of possibility to think that we might see a brief spike towards or even into the .2s today, after all, this is AIM and there are plenty of others who've had such spikes on this kind of in an RNS. Does anyone remember SAR in August 2012?!
The waiting is well worth with this good RNS . Now pyc is moving to VT clinical stage . This is the big stage for pyc and very big improvement in our technology next RNS is Cardiac Toxicity card should be out very soon too .gla
Continues to confirm god progress. Not sure what the sp impact will be - PYC still seems to be off most peoples radar but although the news is sparse each release builds on the previous one - "one day Rodney we will all be millionaires" Still it's of risk but with no good will in the SP this has to be a good buy IMHO of course
We have now extended and adapted our preclinical model to predict efficacy in the clinic, thus creating the "Virtual Tumour Clinical". This is the culmination of a 6 month study collaborating with the National Cancer Institute (NIH, Bethesda, MD). Here we show a comparative study of the preclinical Virtual Tumour and of the Virtual Tumour Clinical version for prostate combination data. The results show how our new model can translate the effect of the drug combination from the preclinical situation to the clinic.
We are also currently in discussions with the first large pharma company who will take on and help us further develop Virtual Tumour Clinical."
Hi matey. I am okay thanks coming back yesterday . Hope you okay too and every things been sorted by now. Val is so slow but that is a procedure . We all waiting for pyc news is over due. But the good things is looks no more fund raising. Gla
Hello Mate, Hope you're okay as well. I'm little bit disappointed with VAL today, but I'm sure they will improve in short term and release good news about the trial. Have a nice day tomorrow Mate. Obelix
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.